MOTS-c (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: 1 to 3 times weekly by subcutaneous injection is the standard cadence, and some practitioners run once weekly across longer courses of up to 10 weeks. This is not a daily peptide. MOTS-c acts over hours rather than weeks, so a morning dose 60 to 90 minutes before Zone-2 cardio aligns with the exercise mimetic mechanism and produces synergistic effects; the week 1 assessment dose is taken fasted in the morning, and MTHFR carriers dose in the morning alongside methyl donors. Cycling 4 to 6 weeks on and 2 to 4 weeks off preserves responsiveness and mimics endogenous MOTS-c, which rises and falls with metabolic demand rather than staying constantly elevated. Higher doses do NOT produce proportionally better effects. At 10 mg/mL a full 10 mg dose is exactly 100 units, so every dose in this protocol fits one U-100 insulin syringe and none of them need splitting. Sites are rotated systematically across abdomen, thighs, and upper arms. Responder phenotype matters: the effect is largest in metabolically compromised individuals such as those with insulin resistance, older or sedentary individuals, and GLP-1 users reporting fatigue, while already lean and metabolically optimized individuals may see minimal benefit.

Results Timeline

Sequence described in the research record. Individual response varies.

• Within 30 minutes of a morning injection: responders report an energy improvement, while a subset reports a crash instead, which may relate to MTHFR status.
• Week 1: a single 5 mg assessment dose taken fasted in the morning, to gauge response before settling into the standard cadence.
• Weeks 2 to 4: metabolic improvements accrue as fuel preference shifts toward fat oxidation.
• Weeks 4 to 6: full first-cycle effects are reported, after which the protocol breaks for 2 to 4 weeks before repeating.

Reconstitution Steps

1. Use ISOTONIC bacteriostatic water (with 0.9% sodium chloride) only. Plain bacteriostatic water causes painful welts and burns. This is not optional.
2. Draw 1.0 mL isotonic bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl until dissolved (do not shake).
5. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 2 to 4 weeks. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe, so 5 mg = 50 units (0.50 mL) and 10 mg = 100 units (1.0 mL).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C (-4 °F) in dry, dark conditions; stable for 12 months or longer.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F); avoid freeze-thaw; use within 2 to 4 weeks.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Stability claim (contested): a widely repeated user report suggests 50% degradation at 2 hours and 90% at 3 hours after reconstitution. It is unverified and traces to a single source; most reconstitute and refrigerate normally without obvious loss of effect.

Supplies Needed

Planning below is based on a 4 to 6 week cycle at 5 mg, 2 times weekly, which works out to 10 mg per week.

Peptide Vials (MOTS-c, 10 mg vial):

• A 4 week cycle uses 40 mg, about 4 vials, and a 6 week cycle uses 60 mg, about 6 vials; the once-weekly 10 week course at 10 mg uses 100 mg, about 10 vials, and an MTHFR-cautious 6 weeks at 3 mg once weekly uses 18 mg, about 2 vials.

Insulin Syringes (U-100):

• Per week: 2 U-100 insulin syringes at 2 injections weekly, since a 5 mg dose is 50 units (0.50 mL) and fits a single 1 mL syringe at this concentration.
• Full cycle: about 8 syringes across 4 weeks and about 12 across 6 weeks; the once-weekly 10 week course needs about 10.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL of isotonic bacteriostatic water containing 0.9% sodium chloride, so one 10 mL bottle covers 10 vials; plain bacteriostatic water will not do.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin.
• Full cycle: about 16 swabs across 4 weeks and about 24 across 6 weeks; one 100 count box covers multiple cycles.

Important Notes

Practical considerations for consistency and safety.

• Isotonic bacteriostatic water is mandatory, not optional. Standard hypotonic bacteriostatic water causes nearly universal sharp burning, welts, and lumps at injection sites that last hours. Isotonic bacteriostatic water containing 0.9% sodium chloride eliminates this, and it is both the single most reported issue with MOTS-c and the most common community fix.
• Morning dose, 60 to 90 minutes before cardio. MOTS-c acts over hours, not weeks, so timing matters for the acute metabolic effect and aligns the dose with the exercise mimetic mechanism.
• MTHFR caution. MOTS-c inhibits the folate cycle: AICAR accumulates and drives AMPK activation, while 5-methylTHF and methionine drop on the methylation side. Carriers of MTHFR C677T or A1298C may experience sharper energy crashes than non-carriers. The master protocol starts known carriers at 2 to 3 mg once weekly paired with methylfolate 400 to 800 mcg, methylcobalamin B12 1 to 2 mg, and glycine 3 g, beginning a week before the first dose, and stopping if crashes persist.
• Do NOT mix with GLP-1 agonists in the same syringe, because the formulations precipitate. Separate injections at different sites are used instead. The stacking rationale is strong, since GLP-1 shifts metabolism toward fat oxidation while MOTS-c raises the mitochondrial capacity to handle that demand, but the two are incompatible in solution.
• Stacking architecture from the master: NAD+ synchronized by IV or IM, since oral precursors take days while MOTS-c acts in hours; SS-31 first as membrane repair, then MOTS-c as metabolic reprogramming; L-Carnitine for CPT-1 transport once fuel preference shifts toward fat; 5-Amino-1MQ to preserve NAD+ in adipose tissue; AOD-9604 in the Morning Partition Stack; and GLP-1 agonists for fatigue management during a deficit.
• Regulatory Note: MOTS-c has no approved therapeutic indication. The only clinical program, the CohBar analog CB4211, completed Phase 1a and 1b in 2021 with positive results but was discontinued over formulation challenges, and no other company currently pursues MOTS-c therapeutics. WADA has prohibited MOTS-c since January 1, 2025 under category S4 (Hormone and Metabolic Modulators), so athletes subject to drug testing are advised to avoid it. For research use only; not for human consumption.

How This Works

MOTS-c activates AMPK, the master energy sensor that responds to exercise, fasting, and metabolic stress. AMPK activation triggers a coordinated adaptive shift: PGC-1alpha driven mitochondrial biogenesis, the same adaptation produced by endurance training; insulin-independent GLUT4 translocation, so cells absorb glucose without requiring insulin signaling, which is valuable in insulin-resistant states; FOXO activation covering stress resistance, autophagy, and metabolic adaptation programs; and a fuel preference shift toward fat oxidation. The mechanism by which MOTS-c inhibits the folate cycle, causing AICAR accumulation that drives AMPK activation, is the basis for both the therapeutic effect and the MTHFR cautions, because the same folate cycle suppression also reduces 5-methylTHF and methionine and creates downstream methylation effects that hit carriers harder. This is reprogramming rather than stimulation: stimulants force output from a depleted system, while MOTS-c teaches the system to generate output differently. Skeletal muscle MOTS-c rises about 12-fold after exercise in young men, circulating levels decline with age and track inversely with insulin resistance, and an exceptionally long-lived Okinawan centenarian population harbors a mitochondrial DNA variant (m.1382A>C) producing a functional MOTS-c polymorphism, which suggests MOTS-c biology may influence human lifespan.

Benefits & Side Effects

Observations from the published record.

• Exercise responsiveness (Nature Communications, 2021): skeletal muscle MOTS-c rises about 12-fold after exercise in young men, and elite athletes show both higher baseline MOTS-c and exercise-responsive increases.
• Correlational human signals: lower MOTS-c independently correlated with reduced insulin sensitivity in obese adults (J Invest Med, 2018), and lower circulating MOTS-c predicted coronary artery disease in CAD patients (Eur Rev Med Pharmacol Sci, 2022).
• Late-life intervention and longevity: animal studies show treatment started at 23.5 months of mouse age, roughly 70 human years, increased physical capacity and healthspan, and the Okinawan m.1382A>C mtDNA polymorphism producing a functional MOTS-c variant tracks with metabolic health and exceptional longevity in that population.
• Metabolic flexibility: fuel preference shifts toward fat oxidation, dependence on continuous glucose availability drops, and fed to fasted transitions smooth out. The widely repeated report of a drop from 18% to 15% body fat in 15 days without diet or exercise changes is a single unverified anecdote, and no other quantified body composition data exists.
• GLP-1 fatigue support: GLP-1 agonists rapidly shift metabolism toward fat oxidation, which is more mitochondrially demanding than burning glucose, and MOTS-c raises oxidative capacity so that instruction arrives at machinery able to execute it. This is reported most often by semaglutide, tirzepatide, or retatrutide users describing a tired but wired state.
• Side effects: injection site burning is nearly universal with non-isotonic bacteriostatic water and rare with isotonic; mild fatigue or crashes occur with initial doses and may reflect the metabolic shift; transient GI discomfort is reported. No serious adverse events appear in the published literature.

Lifestyle Factors

Complementary strategies for best outcomes.

• Zone-2 cardio 60 to 90 minutes after the injection. MOTS-c amplifies exercise adaptations, so without the exercise stimulus the signal arrives but does less; fasted morning training aligns with the AMPK and fat oxidation bias MOTS-c reinforces.
• Adequate protein at 1.6 to 2.2 g/kg supports the recomposition side of the framework, and sleep of 7 to 9 hours protects it, since sleep deprivation directly opposes the AMPK and mitochondrial biogenesis adaptations MOTS-c drives.
• Carbohydrate quality and timing. Glucose spikes oppose the fat oxidation bias; carbohydrate paired post-workout is fine, while ad-lib snacking blunts the protocol.
• Alcohol minimization and methylation support. Ethanol metabolism is a direct mitochondrial stressor that opposes the recovery MOTS-c supports, and MTHFR carriers pair the protocol with methylfolate 400 to 800 mcg, methylcobalamin B12 1 to 2 mg, and glycine 3 g daily, starting one week before the first dose.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Lee C et al. MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance (Cell Metab, 2015).
2. Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator (Nat Commun, 2021).
3. Kim KH et al. MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress (Cell Metab, 2018).
4. Wan W et al. MOTS-c effects and mechanisms related to stress, metabolism and aging (J Transl Med, 2023).
5. Fuku N et al. MOTS-c: a player in exceptional longevity? Okinawan centenarian m.1382A>C variant (Aging Cell, 2015).
6. Mohtashami Z et al. Folate cycle inhibition and AICAR-AMPK axis as MOTS-c mechanism (2022).